Background: Rapid sequence induction (RSI) is indicated in various situations. Succinylcholine has been the muscle relaxant of choice for RSI, and rocuronium has become an alternative medicine for patients who cannot be administered succinylcholine for various reasons. Although rocuronium has the most rapid onset time among non-depolarizing muscle relaxants, the standard dose of rocuronium (0.6 mg/kg) takes 60 seconds to achieve appropriate muscle relaxation. We evaluated intubating conditions using the “modified timing principle ” with rocuronium and succinylcholine. Methods: In this prospective controlled blinded study, all patients received 1.5 μg/kg fentanyl intravenously with preoxygenation for 2 minutes and were randomized to...
peer reviewedBackground: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This st...
Background: The evidence base for the widely accepted standard regimen of succinylcholine for rapid...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
Background: Succinylcholine commonly produces frequent adverse effects, including muscle fasciculati...
The study is based on succinylcholine which is a routine muscle relaxant for pediatric patients. Roc...
Background: Rapid and complete reversal of neuromuscular blockade (NMB) is desirable at the end of s...
Background: Succinylcholine remains the muscle relaxant of choice for rapid sequence induction (RSI...
Background: Although cisatracurium has many advantages in anesthetic practices, the best choice of a...
INTRODUCTION: Neuromuscular blocking agents are commonly used to facilitate tracheal intubation. A...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
Introduction. The aim of the study was to determine intubation conditions in the patients receiving ...
peer reviewedBackground: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This st...
Background: The evidence base for the widely accepted standard regimen of succinylcholine for rapid...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
Background: Succinylcholine commonly produces frequent adverse effects, including muscle fasciculati...
The study is based on succinylcholine which is a routine muscle relaxant for pediatric patients. Roc...
Background: Rapid and complete reversal of neuromuscular blockade (NMB) is desirable at the end of s...
Background: Succinylcholine remains the muscle relaxant of choice for rapid sequence induction (RSI...
Background: Although cisatracurium has many advantages in anesthetic practices, the best choice of a...
INTRODUCTION: Neuromuscular blocking agents are commonly used to facilitate tracheal intubation. A...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
Introduction. The aim of the study was to determine intubation conditions in the patients receiving ...
peer reviewedBackground: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This st...
Background: The evidence base for the widely accepted standard regimen of succinylcholine for rapid...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...